Table 3.
Simulated probability (%) of target attainments (C0) according to CYP3A genotype and Tac dosage.
| C0 targets | CYP3A Cluster | Tac simulated doses (mg) |
||||
|---|---|---|---|---|---|---|
| 2.5 | 5 | 7.5 | 10 | 15 | ||
| 2.5 ng/ml | PM | 91.7% | 97.5% | 98.4% | 98.8% | 98.9% |
| IM | 82.5% | 95.9% | 97.9% | 98.5% | 98.7% | |
| EM | 64.1% | 91.4% | 96.0% | 97.9% | 98.2% | |
| 7.5 ng/ml | PM | 31.8% | 79.1% | 91.7% | 95.1% | 97.1% |
| IM | 17.7% | 61.0% | 82.5% | 91.2% | 94.2% | |
| EM | 12.6% | 50.5% | 64.1% | 79.3% | 87.0% | |
| 10 ng/ml | PM | 11.3% | 60.8% | 84.9% | 91.7% | 94.7% |
| IM | 8.1% | 45.7% | 68.0% | 82.5% | 89.3% | |
| EM | 7.2% | 33.9% | 55.6% | 64.1% | 76.1% | |
| 15 ng/ml | PM | 7.0% | 31.8% | 60.8% | 79.1% | 88.2% |
| IM | 6.5% | 17.7% | 45.7% | 61.0% | 73.8% | |
| EM | 6.3% | 12.6% | 33.9% | 50.5% | 58.8% | |
| 17.5 ng/ml | PM | 6.5% | 20.3% | 48.2% | 69.7% | 82.5% |
| IM | 6.3% | 10.3% | 35.8% | 52.6% | 64.9% | |
| EM | 6.3% | 7.8% | 23.9% | 42.3% | 53.9% | |
| 20 ng/ml | PM | 6.4% | 11.3% | 38.6% | 60.8% | 76.3% |
| IM | 6.3% | 8.1% | 25.9% | 45.7% | 56.9% | |
| EM | 6.3% | 7.2% | 17.2% | 33.9% | 47.6% | |